Form 4: Acadia Pharmaceuticals Executive Sells Shares

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reported a sale of common stock under a Rule 10b5-1 trading plan.

Summary

• James Kihara, the Principal Accounting Officer of Acadia Pharmaceuticals Inc., has reported a transaction involving the sale of company stock.
• The transaction occurred on June 26, 2026, and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025.
• A total of 11,421 shares of common stock were sold at a weighted average price of $26.0846.
• The sale was conducted in multiple transactions with prices ranging from $25.88 to $26.265.
• Following the sale, Kihara beneficially owns 13,088 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the insider sale, despite it being executed under a pre-planned Rule 10b5-1 trading plan.

Negatives

• An executive sold a significant number of shares, which could be perceived negatively by the market.

Risks

• The sale of shares by a key executive could signal a lack of confidence in the company's future performance, although it was conducted under a pre-planned trading strategy.
• The weighted average sale price indicates a range of transactions, and the specific details of each sale at different price points are not fully disclosed in this filing.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under Rule 10b5-1 plans, are closely monitored by investors. While these plans are designed to avoid accusations of insider trading by establishing a predetermined schedule for sales, they can still influence market perception of an executive's confidence in the company's stock.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, potentially impacting share price, although the Rule 10b5-1 plan mitigates concerns about illegal insider trading.
• Employees: May also view the sale with concern, depending on their own investment in company stock.
• Management: The sale by a Principal Accounting Officer could lead to increased scrutiny of future transactions.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan.
• Investors will likely monitor future filings for any additional insider transactions.

Key Dates

Recommendation

The filing reports a stock sale by an executive under a pre-established trading plan. While insider selling can be a negative indicator, the Rule 10b5-1 plan suggests the sale was planned in advance and not based on recent non-public information. Without other significant financial or strategic news, this transaction alone warrants a 'hold' recommendation, advising investors to monitor further developments.

Keywords

Acadia Pharmaceuticals, ACAD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Principal Accounting Officer, James Kihara